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Abstract
It is commonly accepted that brain phospholipids are highly enriched with long chain 
polyunsaturated fatty acids (PUFAs). However, the evidence for this remains unclear. We used 
HPLC-MS to analyze the content and composition of phospholipids in rat brain and compared it to 
the heart, kidney, and liver. Phospholipids typically contain one PUFA, such as 18:2, 20:4, or 22:6, 
and one saturated fatty acid, such as 16:0 or 18:0. However, we found that brain phospholipids 
containing monounsaturated fatty acids in the place of PUFAs are highly elevated compared to 
phospholipids in the heart, kidney, and liver. The relative content of phospholipid containing 
PUFAs is ∼60% in the brain whereas it is over 90% in other tissues. The most abundant species of 
phosphatidylcholine (PC) is PC(16:0/18:1) in the brain, whereas PC(18:0/20:4) and PC(16:0/20:4) 
are predominated in other tissues. Moreover, several major species of plasmanyl and plasmenyl 
phosphatidylethanolamine are found to contain monounsaturated fatty acid in the brain only. 
Overall, our data clearly show that brain phospholipids are the least enriched with PUFAs of the 
four major organs, challenging the common belief that the brain is highly enriched with PUFAs.
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Introduction
It is commonly stated that the brain is highly enriched with polyunsaturated fatty acids 
(PUFAs) [1-3], implying that the brain contains higher amounts of PUFAs than other tissues 
[4, 5]. Furthermore, the high content of PUFAs has been proposed to be responsible for the 
high vulnerability of the brain to ischemia/reperfusion injury [6-8]. However, little evidence 
has been provided to support the high enrichment of PUFAs in the brain.
A majority of cellular fatty acids are esterified to phospholipids [9, 10]. Phospholipids are 
composed of a diacylglycerol moiety attached to a phosphate group, which in turn is 
connected to various head groups. Two acyl chains derived from fatty acids are attached to 
the first and the second carbons of the glycerol moiety, denoted as the sn-1 and sn-2 
positions, respectively. Typically, saturated fatty acids or monounsaturated fatty acids 
(MUFAs) are present at the sn-1 position and PUFAs, such as 20:4, and 22:6, at the sn-2 
position of phospholipids [11-13]. Phospholipids containing MUFAs at the sn-2 position are 
also found. The relative content of species containing PUFAs and species containing 
MUFAs at the sn-2 position determine the abundance of PUFAs in a tissue. However, 
different combinations of the head groups and the acyl chains give rise to numerous isobaric 
and isomeric species, which make analysis of phospholipids highly challenging.
Due to this challenge, analyses of phospholipids are often focused on specific classes or 
species of phospholipids [14-16]. Moreover, the acyl chain composition is often examined 
following trans-esterification [17-20]. These analyses discovered an abundance of 18:1 and a 
lack of 18:2 in brain phospholipids [21, 22]. However, the limitations of the trans-
esterification method, the low recovery of fatty acids from plasmalogens [14] and the loss of 
information on the original molecular structure, prevented capturing many key aspects of 
phospholipids.
Previously, we developed a normal-phase HPLC-MS method for comprehensive analysis of 
phospholipids [21]. The method includes extraction of lipid mixtures and separation of the 
phospholipid fraction using solid-phase extraction. Class separation by normal-phase HPLC 
prior to MS analysis allows the generation of full spectra of each class of phospholipid. The 
full spectra are particularly useful for comparing the molecular composition of each class of 
phospholipids between different samples.
Using this established HPLC-MS method, we analyzed the content and composition of 
phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS), 
phosphatidylglycerol (PG), phosphatidylinositol (PI), and cardiolipin (CL) from the brain, 
heart, kidney, and liver. We also analyzed the content of lysophospholipids and free fatty 
acids to validate our sampling procedure and to support our conclusion. This thorough 
analysis revealed that the brain is least enriched with PUFAs of the four organs examined in 
this study.
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Materials and Methods
Chemicals and materials
“Reagent-grade chemicals and HPLC-grade solvents were purchased from major 
commercial suppliers (Fisher Scientific and Sigma Aldrich). Standard phospholipids, 
PC(16:0/16:0), PE(16:0/16:0), PG(16:0/16:0), PI(16:0/18:1), PS(16:0/16:0), CL(18:2)4, 
were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 1,2-Dipalmitoyl-sn-
glycero-3-phospho-N-methylethanolamine (PME), the internal standard, was purchased 
from Santa Cruz Biotech (Santa Cruz, CA). Pre-packed silica gel SPE columns were 
purchased from Biotage (Charlotte, NC).
Animals
The experimental protocol was approved by the Institutional Animal Care and Use 
Committee. Adult male Sprague–Dawley rats (weight 465–530 g, Charles River Production, 
Wilmington, MA) were anesthetized with 4% isoflurane and sacrificed by decapitation to 
harvest the brain, heart, kidney, and liver. Rats were maintained under a 12-h light/dark cycle 
with free access to food and water and used without starvation. The tissues were 
immediately pulverized in liquid nitrogen and stored at -80 °C until analyzed.
Extraction of Phospholipids
Extraction and separation of phospholipids was performed as previously reported [23, 24]. 
Briefly, ∼ 1 mg of homogenized tissue was treated with 950 μL of chloroform:methanol 
(2:1, v:v) solution containing butylated hydroxytoluene (2 mM) and 50 μL of potassium 
phosphate buffer (100 mM, pH 7.4). The organic solution was added first to inactivate any 
enzymatic reaction that may facilitate the hydrolysis of phospholipids. Phospholipid 
mixtures were separated using solid-phase extraction [23] and reconstituted in 200 μL of 
isopropanol:t-butyl methyl ether:ammonium formate (34:17:5, v:v:v) solution. For HPLC-
MS analysis, 20 μL phospholipid mixture was injected into the HPLC.
Normal-phase HPLC-MS and MS/MS
The HPLC conditions for separating each class of phospholipids were reported previously 
[23]. A nucleosil diol column (5 μm, 3×250 mm) (Macherey-Nagel, Duren, Germany) was 
used. Eluent A contained isopropanol:t-butyl methyl ether:ammonium formate (34:17:5, 
v:v:v) and eluent B contained methanol. Aqueous ammonium formate was prepared by 
dissolving 295 mg of ammonium formate and 1.9 mL of formic acid in 50 mL of water. The 
gradients used for the 40 min chromatogram were as follows: 100 % A for 20 min, 100% A 
to 20% A over 6 min, 20% A for 8 min, 20% A to 100% A over 1 min, and hold 100% A for 
5 min. The flow rate was 0.3 mL/min and the column temperature was 30°C. MS and 
MS/MS data were collected using a Thermo LTQ XL spectrometer (Thermo Scientifics, San 
Jose, CA) operated in the negative ion mode.
Analysis of molecular species in each class of phospholipids
The content of each class of phospholipids was expressed as a mole fraction of the total 
phospholipids. Concentrations of individual classes were determined using standard curves 
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and an internal standard as previously reported [23]. Standard curves were generated using 
the standard phospholipids with PME as an internal standard. The concentration of PE 
includes both diacyl PE and PE plasmalogens (PEP), which contain an ether linkage at the 
sn-1 position. Species between diacyl PE and PEP were distinguished based on their 
molecular weights and fragmentation patterns by MS/MS [25]. The concentrations of PE 
and PS in brain tissue were extrapolated from the standard curve.The abbreviations 
previously described for ether alkyl chains of PEP were used [25].
The content of individual species within a class was calculated from the area of M0 and M1 
peaks using the Quan Browser in Xcalibur Version 2.2 software [26]. The content of each 
species of phospholipid was expressed as a percentage of total content of the class of 
phospholipid. We only included species, whose relative content is greater than 1% of the 
total phospholipid content in each class. Assignment of individual species in each class of 
phospholipids was made based on retention time and MS and MS/MS analyses [23]. If a 
peak contains more than one major isomeric species (over 10% of the total peak intensity), 
the area was corrected based on the relative abundance determined by MS/MS. The relative 
intensity of CL and PS species was calculated based on the relative intensity of each peak 
compared to total CL and PS peaks identified. The isotope abundance and the peak ratio of 
sodium adduct of individual species were calculated from authentic standards purchased 
from Avanti Polar Lipids. All data are presented as mean ± standard deviation.
Measurement of free fatty acids
To measure free fatty acids, 20 mg homogenized tissue were extracted in 500 μL of 
methylene chloride: methanol: isopropanol 25:65:10 (v/v/v), with 50 μg/mL butylated 
hydroxytoluene. UPLC (Ultra-performance LC) was performed using a 1.8 μm particle 100 
× 2.1 mm id HSS T3 column (Waters, Milford, MA) coupled to a quadrupole time-of-flight 
(TOF) mass spectrometer (AB SCIEX, TripleTOF 5600) operated in information-dependent 
MS/MS acquisition mode. The LC and MS conditions were as previously described [27]. 
The quantification of free fatty acids was performed using MutliQuant Software version 
3.0.2 (SCIEX), based on the accurate masses and retention times of each fatty acid.
Results
Concentration of phospholipids
Ion chromatograms of individual classes of phospholipids from heart tissue separated by 
normal-phase HPLC are shown in Fig. S1. The retention time of each class of phospholipids 
is similar to the previous reports [23, 26]. The concentrations of individual classes of 
phospholipids are shown in Table 1. PE, including diacyl PE and PEP, is the most abundant 
class of phospholipids in the brain, heart, and kidney, accounting for 55% of the total 
phospholipid content in the brain, 49% in the heart, and 48% in the kidney. PC is the second 
most abundant, making up 31%, 38%, and 35% of total phospholipids in the brain, heart and 
kidney, respectively. In the liver, PC is the most abundant species, contributing 48% of the 
total membrane phospholipids, while PE contributes 35%. The lower content of PE in the 
liver compared to other tissues is due to the minimal amount of PEP found in the liver. PS is 
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another major class in the brain, accounting for ∼8%. In the kidney and liver, PI is the third 
abundant class accounting for ∼ 10% and 13% of total phospholipids, respectively.
Molecular composition of PE
The mass spectra of PE including diacyl PE and PEP from the brain, heart, kidney, and liver 
are shown in Fig. 1, and the molecular structures of the major species determined by MS/MS 
are listed in Table 2. Most MS peaks are composed of one dominant species with more than 
90% of the peak intensity. If the relative content of minor isomeric species is more than 20% 
of the major isomers, these minor species are also noted in Table 2. Fig. 2 shows the 
calculated mole percentages of the major species of PE as described in the material and 
methods section. We provide the relative contents of individual species for an easy 
comparison of phospholipid profiles between tissues. However, the relative contents can be 
readily converted to absolute concentrations using the values provided in Table 1.
In brain and heart tissue, PE(18:0/22:6) and PE(18:0/20:4) are the most abundant species, 
accounting for 11% and 8% in the brain (Fig. 2a), respectively and 20% and 16% in the 
heart (Fig. 2b), respectively. In the kidney, arachidonic acid containing species, 
PE(18:0/20:4) and PE(16:0/20:4), account for 28% and 9% respectively (Fig. 2c). In the 
liver, one dominant species, PE(18:0/20:4), accounts for 30% of total PE. Other major 
species, PE(18:0/22:6), PE(16:0/20:4), and PE(18:0/22:6), also make up a substantial 
portion of PE in the liver (Fig. 2d). Interestingly, brain PE is also comprised of species 
containing MUFAs, such as PE(18:0/18:1) and PE(18:1/18:1), whereas these species are 
negligible in other tissues. Since PE(18:1/18:1) found in the brain has the same molecular 
weight (m/z 743) as PE(18:0/18:2) found in other tissues, we provide MS/MS spectra of the 
nominal peak at 743 as an example to compare the structure of the PE species between brain 
and other tissues (Fig. 3). In the brain, the peak at 281 corresponding to 18:1 and the peak at 
478 corresponding to octadecenoyl glycerol confirm the structure as PE(18:1/18:1) (Fig. 3a). 
In the heart, the peaks at 279 and 283 corresponding to free fatty acids 18:2 and 18:0, 
respectively, and the peak at 480 corresponding to octadecanoyl glycerol confirm the 
structure as PE(18:0/18:2) (Fig. 3b). The MS/MS spectra of the MS peak at 743 in the 
kidney and liver are the same as the heart. Overall, most major PE species contain PUFAs, 
such as 22:6 and 20:4, and the relative content of these species are not higher in the brain.
Molecular composition of PEP
PE contains a substantial amount of plasmalogens (Fig. 4), which are known to be enriched 
with PUFAs. The overall concentration of PEP is the highest in the brain. The major species 
of PEP contain PEP(16:0/20:4), PEP(18:0/20:4), PEP(16:0/22:6), and PEP(18:0/22:6). In 
addition to these PUFA containing species, significant levels of PEP species containing 18:1 
at the sn-2 position are present in brain tissue as well (Fig. 4a). Interestingly, 
PEP(16:0/18:1), PEP(18:1/18:1), and PEP(18:0/18:1) account for 20% of the total PE 
content, which is similar to the relative abundance of the five major PEP species containing 
PUFAs (26%) (Fig. 4a).
In the heart, the major species of PEP, such as PEP(16:0/20:4), PEP(16:0/22:6), 
PEP(18:0/20:4), and PEP(18:0/22:6), all contain long chain PUFAs (Fig. 4b). These species 
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account for ∼26% of the total PE in heart tissue. A similar pattern is observed in the kidney, 
but with less overall PEP content (Fig. 4c). The relative content of PEP of total PE is 19% in 
kidney tissue. The kidney also contains a detectable amount of species containing MUFAs, 
such as PEP(16:0/18:1). Liver contains a dramatically lower content of PEP, accounting for 
2% of total PE in liver tissue (Fig. 4d). As was seen in the profile of PE, only brain PEP is 
comprised of significant amounts of species containing MUFAs.
We also show an example of MS/MS spectra a PEP species with molecular weight of 701 
from the brain and kidney (Fig. 3c and d). In the brain, the peak at 436 corresponding to 
hexadecenyl glycerol and the peak at 281 corresponding to 18:1 confirm the structure as 
PEP(16:0/18:1) (Fig. 3c). The peak at 418 is the dehydrated form of the peak at 436 and the 
peak at 255 is from 281-CO2. The same peaks at 436 and 281 in the kidney show that the 
PEP(16:0/18:1) in the major species is under the MS peak at 701 (Fig. 3d). In addition, the 
peak at 438 corresponding to hexadecanyl glycerol and the peak at 279 corresponding to 
18:2 confirm the coexistent of plasmanyl PE (16:0/18:2) as a minor species of the same MS 
peak in the kidney (Fig. 3d).
Molecular composition of PC
The mass spectra of PC from heart and brain tissues are shown in Fig. 5 and the 
concentrations of major species of PC determined by MS/MS are shown in Fig. 6. 
Interestingly in the brain, the most abundant species is PC(16:0/18:1) (Fig. 6a). In addition, 
species containing saturated fatty acids or MUFAs, such as PC(16:0/16:0), PC(18:1/18:1) 
and PC(18:0/18:1), are also abundant. These four species together account for ∼ 54% of the 
total PC content in brain tissue, which is significantly higher than ∼15% of the content of 
major PUFA-containing species combined. Again, PC species containing 18:2 are also 
negligible in brain tissue (Fig. 6a).
In the heart, PC species containing 20:4, PC(16:0;20:4) and PC(18:0;20:4), are the two 
major species, while species containing 22:6 are also abundant (Fig. 6b). Kidney tissue 
includes multiple major species, such as PC(16:0/18:2), PC(16:0/20:4) and PC(18:0/20:4) as 
well as MUFA containing species (Fig. 6 c). Liver tissue also contains PC(16:0/18:2), 
PC(16:0/20:4) and PC(18:0/20:4) as a major PC species. It is notable that no considerable 
amounts of PC containing MUFAs are observed in the liver. Overall, Fig. 5 and 6 show that 
PC in the brain contains much higher amounts of MUFAs than other organs and liver PC is 
most dominated with PUFAs.
Molecular composition of PS
Mass spectra of PS are shown in Fig. 7 and the concentrations of major species of PS are 
shown in Fig. 8. In the brain, two major species of PS are the PS(18:0/22:6) and 
PS(18:0/18:1), which account for 51% and 26% of the total PS content, respectively. In the 
brain, a total of 65% PS contains PUFAs whereas over 90% of PS contains PUFAs in other 
tissues. The most abundant species of PS is PS(18:0/22:6 in the brain and heart and 
PS(18:0/20:4) in the kidney and liver. PS species containing 18:2 is not detectable in the 
brain, but readily detectable in other organs.
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Molecular composition of PI and PG
The MS spectra of PG and PI are shown in Fig. S2 and S3 and the concentrations of 
individual species of PI and PG are shown in Fig. 9. The molecular compositions of PI and 
PG are similar between tissues that PI and PG each has one dominant species, PI(18:0/20:4), 
and PG(18:0/18:1), respectively. Major species of PI only contains PUFAs, whereas PG is 
predominated with MUFAs. As was seen in other classes of phospholipid, PI and PG species 
containing 18:2 are negligible in the brain.
Composition of CL
MS spectra of CL are shown in Fig. 10. Fig. 10a shows the MS spectrum of CL from brain 
tissue. The CL composition in the brain is highly diverse and markedly differs from its 
composition in the heart, kidney, and liver (Fig. 10 b-d). The peak at 1448 corresponding to 
tetra-linoleoyl CL, noted as CL(18:2)4 is the major species in the heart, kidney, and liver as 
commonly observed [28] In the kidney and liver, the enhanced peaks at 1450 and 1472 show 
that CL(18:2)3(18:1) and CL(18:2)3(20:4) are also abundant. CL(18:2)4 accounts for 83% of 
the total CL content in the heart, 48% in the kidney, and 45% in the liver. However, the peak 
at 1448 in brain is an only minor peak (Fig. 10a). Moreover, the MS/MS spectra revealed 
that the peak 1448 is comprised of several isomeric species (Fig. S4). Considering the 
relative peak intensity of 1448 by MS and the number of isomers by MS/MS, we conclude 
that CL(18:2)4 is less than 1% of the total CL content in the brain. MS/MS analysis also 
shows that most CL MS peaks are comprised of multiple isomers. Therefore, the total 
number of CL species in the brain should be several times more than the number of the 
peaks shown in the MS spectrum (Fig. 10a). Due to this enormous number of species, 
characterization of CL in the brain is difficult to achieve.
Content of lysophospholipids and free fatty acids
Several species of lysoPC, lysoPE, and lysoPI are detected from whole tissue. Fig. S5 shows 
the relative peak area of individual species of lysophospholipids compared to the peak area 
of the corresponding class of phospholipids. The common species contain 16:0 or 18:0 as 
these are the common fatty acid at the sn-1 position of PE and PC. Consistent with the high 
abundance of 18:1 in brain tissue, lysoPE and lysoPI species containing 18:1 are readily 
detectable in brain tissue.
Fig. S6 shows the relative content of free fatty acids from 20 mg of each tissue. Since the 
contents of free fatty acids are estimated based on their peak areas, the data may not be 
appropriate to compare the levels between fatty acids, however, can be used to compare each 
fatty acid level between tissues. The data clearly show that the levels of free fatty acids in the 
brain are not higher than in other tissues. The amount of 16:0 is the most abundant in liver 
tissue compared to in other tissues. The level of 18:0 is similar in all tissues. Compared to 
the liver, similar levels of 20:4 and 22:4 are detected in the brain, but all other PUFAs, 
including 22:6, are higher in the liver. It is also notable that the brain contains a much lower 
content of 18:2 compared to other tissues, consistently with the lack of phospholipid species 
containing 18:2 in this tissue. Overall, the results from lysophospholipids and free fatty acids 
confirm that there is no significant decomposition of phospholipids from the tissues during 
sampling procedures that may interfere with phospholipid analysis.
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Discussion
Brain phospholipids are least enriched with PUFAs
Although it is commonly cited that the brain phospholipids are highly enriched with PUFAs 
[29], the evidence for this is limited. Here, we show that the brain has the lowest mole 
fraction of PUFA-containing phospholipid species (Fig. 11). The content of overall PUFA 
containing species is ∼60% of total phospholipid in the brain, whereas it is over 90% in the 
heart and kidney and ∼ 95% in the liver. Consequently, the concentrations of PUFA-
containing phospholipids per mg tissue are also lower in the brain than in the liver. One may 
argue that PUFAs are enriched in a special area of brain. In fact, fatty acid composition 
differs depending on the areas of the brain [30, 31], but the difference is not sufficient to 
make an area of the brain more enriched with PUFA than the heart, kidney, or liver. Overall, 
our results are not consistent with the common belief that the brain is highly enriched with 
PUFA.
Typical phospholipids in mammalian tissues contain PUFAs at the sn-2 position and 
saturated fatty acids at the sn-1 position. Phospholipids containing MUFAs at the sn-2 
position are also found, but to a much lesser extent. Therefore, almost every tissue is 
enriched with PUFAs, but the abundance of PUFAs has been emphasized only in the brain. 
Consequently, it is believed that the PUFA content in brain phospholipids is higher than in 
other tissues [4, 5]. Furthermore, the high content of PUFAs, such as 20:4 and 22:6, is 
hypothesized to be a major factor responsible for the vulnerability of the brain to ischemia/
reperfusion injury [6-8, 10, 32].
Our result that brain phospholipids are least enriched with PUFAs of the four organs does 
not support this hypothesis. However, the finding does not rule out potential roles that 
PUFAs play in ischemic brain damage. Along with other alterations, such as glutamatergic 
dysregulation [33], PUFAs may be an important mediator in brain damage. It may be not the 
amount of PUFAs but the cellular conditions of the brain that facilitate PUFA-mediated 
pathways that may be a contributing factor to the vulnerability of the brain. In this light, 
lowering the PUFA content in membrane phospholipids may be the self-regulation of the 
brain to protect itself from ischemia. Consistent with this, the brain phospholipid is less 
responsive to the PUFA content in diets than other tissues [34, 35].
HPLC-MS analysis of phospholipid
Due to the existence of numerous isobaric and isomeric species, quantitation of 
phospholipids is challenging. Various methods have been applied to quantify phospholipids, 
however, the results differ depending on the methods used [20, 36-39]. Since the 
development of electrospray ionization, mass spectrometry is the most common method 
used to analyze phospholipids [40-42]. Differential ion mobility spectrometry has also 
become available and is a promising technique for the differentiation of isomers with or 
without silver ion adduction; however, it is limited to only a few number of MS methods 
[43].
We used normal-phase HPLC-MS for this study. Normal phase-HPLC separates 
phospholipids by class based on their retention times [23].This class separation provides a 
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full mass spectrum for each class of phospholipid (Fig. 1, 5, 7, and 10). Identification of a 
species by MS and MS/MS compared with the mass of the species in these full spectra 
reduces chances for false assignments and omission of significant species. In addition, the 
concentration of each phospholipid species calculated using automated methods can be 
cross-validated by comparing the calculated values with the intensities of the corresponding 
peaks in this full spectrum. For example, the concentrations of PE(16:0/20:4) and 
PE(16:0/20:4) presented in Fig. 2d can be matched with the peaks at 766.8 and 738.8 in Fig. 
1d, respectively. With fully validated sampling and quantitation procedures [23], the normal 
phase HPLC-MS method is shown to be advantageous for comparing phospholipid profiles 
between multiple tissues.
The lack of 18:2 in brain phospholipids including CL
The absence of species containing 18:2 in brain phospholipids has been reported previously 
[22]. It is interesting, however, that the brain limits the usage of 18:2 even for the synthesis 
of CL. In mitochondria, the final structure of CL is determined by the remodeling step, 
which preferentially incorporates 18:2 into CL [44, 45]. Consequently, CL(18:2)4 is often 
found to be the dominant species in most mammalian tissues [46]. It seems that the relative 
abundance of fatty acids is also an important factor in the selection of fatty acids for CL 
remodeling. Limiting the usage of 18:2 for the synthesis of CL may have caused the 
incorporation of more freely available fatty acids into CL, resulting in the highly diverse CL 
composition observed in the brain. This argument is supported by the fact that CL 
composition is readily affected by the fat contents in the diet [47-49]. This unique CL 
composition suggests that at least for brain mitochondria, neither the symmetry of CL nor 
preserving CL(18:2)4 is important. This explains why brain function is not affected in Barth 
syndrome patients, who have a defective metabolism for the use of 18:2 for CL.
In conclusion, unlike the common belief that brain is highly enriched with PUFAs, we have 
demonstrated that brain phospholipids contain lower contents of PUFAs than phospholipids 
in the heart, kidney and liver. The mole fraction of phospholipids containing PUFAs in the 
brain is ∼60%, which is significantly lower than over 90% found in other organs. This low 
PUFA content is due to high content of 18:1, particularly in PC, PEP, and PS. Overall, it is a 
unique feature that brain phospholipids contain significant amounts of MUFAs, making 
brain phospholipid least enriched with PUFAs of the four major organs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
MS spectra of PE from brain (A), heart (B), kidney (C), and liver (D) tissues. Major species 
of diacyl and plasmenyl PE in heart, kidney, and liver tissues contains PUFA at the sn-2 
position (A) whereas PE species containing MUFA (labeled in boxes) are highly enriched in 
brain tissues.
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Fig. 2. 
Relative contents of major species of phosphatidylethanolamine in the brain (A), heart (B), 
kidney (C), and liver (D). (data are presented as mean ± standard deviation, n=6). Closed bar 
=MUFA, open bar =PUFA.
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Fig. 3. 
MS/MS spectra of PE species with m/z 742.8 from the brain (A) and the heart (B), and PEP 
species with m/z 701.9 from the brain (C) and the kidney (D). The peak at 478 
corresponding to octadecenoyl glycerol and the peaks at 281 corresponding to 18:1 confirm 
the structure as PE(18:1/18:1) (A). The peak at 480 corresponding to octadecanoyl glycerol 
and the peaks at 279 and 283 corresponding to 18:0 and 18:2 confirms the structure as 
PC(18:0/18:2) (B). The peak at 436 corresponding to hexadecenyl glycerol and the peak at 
281 corresponding to 18:1 confirm the structure as PEP(16:0/18:1). The peak at 418 is 
dehydrated form of 436 and the peak at 255 is from 281-CO2. (C). The peaks at 436 and 281 
confirms the structure of the major species as PEP(16:0/18:1), and the peak at 438 
corresponding to hexadecanyl glycerol and the peak 279 corresponding to18:2 confirms the 
structure of the minor species as plasmanyl PE(16:0/18:2) (D).
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Fig. 4. 
Relative contents of plasmenyl phosphatidylethanolamine in the brain (A), heart (B), kidney 
(C), and liver (D) (data are presented as mean ± standard deviation, n=6). Closed bar 
=MUFA, open bar =PUFA.
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Fig. 5. 
MS spectra of PC from brain (A), heart (B), kidney (C), and liver (D) tissues. Three most 
abundant PC species in brain tissue contain saturated fatty acid or mono unsaturated fatty 
acids (labeled in boxes, 779, PC(16:0/16:0); 805, PC(16:0/18:1); and 833, PC(18:0/18:1) 
(A). Major PC species in liver tissue contain PUFA (D).
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Fig. 6. 
Relative contents of major species of PC from the brain (A), heart (B), kidney (C), and liver 
(D) (data are presented as mean ± standard deviation, n=6). Closed bar =Saturated or 
MUFA, open bar =PUFA.
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Fig. 7. 
MS spectra of PS from brain (A), heart (B), kidney (C), and liver (D) tissues. PS species 
containing MUFA (788.7, PS(18:0/18:1) is significantly higher in the brain than other 
tissues.
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Fig. 8. 
Relative contents of major species of PS from the brain (A), heart (B), kidney (C), and liver 
(D) (data are presented as mean ± standard deviation, n=6). Closed bar =MUFA, open bar 
=PUFA.
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Fig. 9. 
Relative contents of major species of PI and PG from the brain, heart, kidney, and liver (data 
are presented as mean ± standard deviation, n=6).
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Fig. 10. 
Mass spectra of CL from brain (A), heart (B), kidney (C), and liver (D) tissues. CL(18:2)4 is 
the major species in the heart, kidney, and liver but only a minor species in the brain.
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Fig. 11. 
Heatmap representation of phospholipid profiles in the brain, heart, kidney, and liver 
generated by Metaboanalyst software v.3.0. Sample intensities were scaled using Pareto 
scaling (high [red] and low [blue]). Heatmap trends show that the contents of phospholipid 
containing MUFA are higher in the brain than in other tissues.
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Table 2
Molecular composition of major phospholipids characterized by MS/MS
brain heart kidney liver
PE
715 16:1/18:1 16:0/18:2 16:0/18:2 16:0/18:2
717 16:0/18:1 16:0/18:1 16:0/18:1
739 16:0/20:4 16:0/20:4
18:2/18:2
16:0/20:4 16:0/20:4
743 18:1/18:1 18:0/18:2 18:0/18:2 18:0/18:2
745 18:0/18:1 18:0/18:1
763 16:0/22:6 16:0/22:6 18:2/20:4
16:0/22:6
16:0/22:6
18:2/20:4
765 18:1/20:4
16:0/22:5
18:1/20:4
16:0/22:5
18:1/20:4 18:1/20:4
16:0/22:5
767 18:0/20:4 18:0/20:4 18:1/20:4 18:1/20:4
773 18:0/ 20:1
789 18:1/22:6 18:1/22:6
791 18:0/22:6 18:0/22:6 18:0/22:6 18:0/22:6
795 18:0/22:4
PEP
701 16:0/18:1 16:0/18:1
m16:0/18:21
723 16:0/20:4 16:0/20:4 16:0/20:4
727 18:1/18:1 18:0/18:2 18:0/18:2
729 18:0/18:1
16:0/20:1
m18:0/18:2
18:0:18:1
m18:0/18:2
737 16:1/20:4
16:0/20:5
16:1/20:4
16:0/20:5
747 16:0/22:6 16:0/22:6 16:0/22:6
749 18:1/20:4 18:1/20:4
16:0/22:5
18:1/20:4
751 18:0/20:4
16:0/22:4
18:0/20:4 18:0/20:4 18:0/20:4
753 m18:0/20:4
757 18:0/20:1
773 18:1/22:6 18:1/22:6
775 18:0/22:6 18:0/22:6 18:0/22:6 18:0/22:6
779 18:0/22:4
PC
779 16:0/16:0 16:0/16:0 16:0/16:0
803 16:0/18:2 16:0/18:2
805 16:0/18:1 16:0/18:1 16:0/18:1 16:0/18:1
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